Biomea Fusion Analyst Ratings
Truist Cuts Biomea Fusion to Hold, Cites Clinical Hold Uncertainty
Biomea Fusion Analyst Ratings
Biomea Fusion Downgraded to Hold at Truist Securities With No Price Target Following Clinical Hold Placed by FDA Last Week
Biomea Fusion Analyst Ratings
Truist Financial Keeps Their Buy Rating on Biomea Fusion (BMEA)
Analysts Are Bullish on Top Healthcare Stocks: Biomea Fusion (BMEA), Day One Biopharmaceuticals (DAWN)
Biomea Fusion Analyst Ratings
Oppenheimer Sticks to Their Buy Rating for Biomea Fusion (BMEA)
Biomea Fusion Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Repligen (RGEN) and Agenus (AGEN)
Barclays Sticks to Its Buy Rating for Biomea Fusion (BMEA)
Biomea Fusion Analyst Ratings
Biomea Fusion (BMEA) Receives a Buy From Scotiabank
Analysts Offer Insights on Healthcare Companies: Humana (HUM), Baxter International (BAX) and Biomea Fusion (BMEA)
Buy Rating Affirmed for Biomea Fusion on Promising BMF-219 Clinical Results and Strong Financial Position
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Biomea Fusion (BMEA) and Soleno Therapeutics (SLNO)
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Intuitive Surgical (ISRG) and Sangamo Biosciences (SGMO)
Truist Financial Issues a Buy Rating on Biomea Fusion (BMEA)
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biomea Fusion (BMEA) and Jasper Therapeutics (JSPR)